genOway Signs a $2 Million Contract with a US-based Biopharmaceutical Firm
News Oct 19, 2007
genOway reports the signing of a contract for up to $2 million in intended services with a leading biopharmaceutical company based in the United States of America.
Under the terms of this 2-year agreement, genOway will provide its client with customized genetically modified mouse lines tailored to the researchers’ needs. Moreover, this agreement can be increased to include additional models.
genOway has been chosen thanks to the company’s expertise and capacity to create highly sophisticated animal models by means of an industrialized production process.
"This contract is the second multi-million dollar deal of the year for genOway. It further confirms that the company is able to propose acceptable offers to large biopharmaceutical companies. genOway is proud to have been chosen by this company and we are very excited about the start of this collaboration" said Alexandre Fraichard, CEO of genOway.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019